Bryan Zimdahl
Senior Director, Clinical Science & Regulatory Affairs Lega Eureka Therapeutics
Bryan Zimdahl is Senior Director, Clinical Science and Regulatory Affairs at Eureka Therapeutics, where he supports the clinical and regulatory development of novel T-cell therapies. Previously, he worked in preclinical development at Eureka Therapeutics, contributing to research on CAR-T cell therapies and approaches for targeting intracellular proteins in solid tumors. His research has included the development and clinical evaluation of the company’s AbTCR platform. Bryan completed postdoctoral training at Stanford University School of Medicine and holds a PhD from Duke University and a BS from Villanova University.
Seminars
Tuesday 9th February 2027
Accelerating Solid Tumour Cell Therapy Development Through Adaptive Trial Design & Regulatory Strategy
1:45 pm
- Optimising eligibility criteria and patient selection strategies to enhance clinical outcomes and accelerate development in solid tumours
- Leveraging adaptive trial designs and proactive regulatory engagement to streamline development pathways and support faster approvals
- Showcasing Phase II clinical data and key learnings to refine development strategies and advance next-generation solid tumour cell therapies
